SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-038429
Filing Date
2024-03-29
Accepted
2024-03-29 09:35:14
Documents
14
Period of Report
2024-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20240329.htm   iXBRL 8-K 40885
2 EX-99.1 sabs-ex99_1.htm EX-99.1 25470
3 GRAPHIC img1871078_0.jpg GRAPHIC 1565706
4 GRAPHIC img1871078_1.jpg GRAPHIC 1009318
  Complete submission text file 0000950170-24-038429.txt   3763423

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240329.xsd EX-101.SCH 45415
17 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240329_htm.xml XML 6438
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 24802278
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)